Skip to content
OpenCapital
Get started

Immuneering Corporation IMRX Q4 2025 Annual earnings

Reported March 6, 2026 · Before market open

Diluted EPS-$0.18Beat by $0.13
EPS estimate-$0.31

Next report

Aug 12, 2026 (in a month)
EPS estimate-$0.26

Versus estimates

Diluted EPS

Q1 2026-$0.21Beat by $0.09
Q4 2025-$0.18Beat by $0.13
Q3 2025-$0.38Miss by $0.01Q2 2025-$0.40In lineQ1 2025-$0.42Miss by $0.01Q4 2024-$0.58Miss by $0.16

Ask the moment Immuneering Corporation reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Immuneering Corporation report Q4 2025 earnings?
Immuneering Corporation (IMRX) reported Q4 2025 earnings on March 6, 2026 before market open.
What were Immuneering Corporation's Q4 2025 revenue and EPS?
Immuneering Corporation reported diluted EPS of $-0.18 for Q4 2025.
Did Immuneering Corporation beat estimates in Q4 2025?
EPS beat the consensus estimate of $-0.31 by $0.13.
How did Immuneering Corporation's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS grew 69.0% from $-0.58.
Where can I find Immuneering Corporation's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001790340-26-000040) and the 10-K periodic report (0001790340-26-000042) directly on SEC EDGAR. The filing index links above go to sec.gov.